Inventor · disambiguated record
Don Zhang
Also filed as: ZHANG DON
16 granted patents·7 pending applications·29 citations·filing 2003–2023
88Inventor score
Top patents by PatentIndex Score
23 records- 0187US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0285US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0376US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0476US7078409B2Fused quinazoline derivatives useful as tyrosine kinase inhibitorsBETA PHARMA INC·Filed 2003·Granted Jul 18, 2006·12 cites·16 claims
- 0573US8822482B2Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereofWANG YINXIANG·Filed 2009·Granted Sep 2, 2014·2 cites·35 claims
- 0669US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 0765US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 0861US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 0960US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 1059US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 1158US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1256US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 1356US9359370B2Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereofBETA PHARMA INC·Filed 2014·Granted Jun 7, 2016·0 cites·13 claims
- 1454US11352341B22H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Jun 7, 2022·0 cites·19 claims
- 1554US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1653US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 1752US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1851US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1950US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 2046US2022079944A12h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesBETA PHARMA INC·Filed 2020·Application pending·0 cites
- 2140US9820721B2Aspiration and biopsy needle apparatus and devices and applications thereofBETA PHARMA INC·Filed 2015·Granted Nov 21, 2017·0 cites·38 claims
- 2237US2005148554A1Anti-inflammatory and anti-thrombotic compounds and their compositionsFiled 2004·Application pending·0 cites
- 2333US9163010B2Indolinone protein kinase inhibitorsZHANG DON·Filed 2012·Granted Oct 20, 2015·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Don Zhang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →